Lymphotactin enhances the in-vitro immune efficacy of dendritoma formed by dendritic cells and mouse hepatocellular carcinoma cells.
OBJECTIVE
To investigate the in-vitro antitumor immune responses of dendritoma formed by mouse hepatocellular carcinoma (HCC) cells and lymphotactin (Lptn) gene modified dendritic cells (DCs).


METHODS
DCs prepared from mouse bone marrow were genetically modified by lymphotactin adenovirus, and fused with H22 cells by polyethylene glycol (PEG). RT-PCR and ELISA were employed to identify lymphotactin expression at mRNA and protein level. Cell phenotypes and fusion efficiency was detected by FACS. The stimulatory effect of DC on T cells was detected by mixed lymphocyte reaction. The cytotoxicity activity against H22 cells was assayed by LDH method.


RESULTS
Lymphotactin could be efficiently expressed by DCLptn/H22 hybridoma. DCLptn/H22 cells could induce potent T cell proliferation effect and generate strong cytotoxic T lymphocyte (CTL) reaction against allogenic H22 cells.


CONCLUSIONS
Lymphotactin genetic modification could enhance the in vitro immune activity of the dendritoma.
Zhang
Hao
H
First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China. haozh@zju.edu.cn
Jiang
Guo-ping
GP
Zheng
Shu-sen
SS
Wu
Li-hua
LH
Zhu
Feng
F
Yang
Zhen-lin
ZL
D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000276:immunology*; D002459:Cell Fusion / Q000379:methods*; D002478:Cells, Cultured; D019744:Chemokines, C / Q000235:genetics / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D007114:Immunization / Q000379:methods*; D008213:Lymphocyte Activation / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
D019744:Chemokines, C; D011994:Recombinant Proteins; C486249:Xcl1 protein, mouse